Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 November 2022, including: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche Holding AG’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors" - Scrip, 11 Nov, 2022.)
(Also see "After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?" - Scrip, 16 Nov, 2022.)
(Also see "Roche’s Alzheimer’s Drug Fails In Phase III Giving Eisai/Biogen A Clear Run" - Scrip, 14 Nov, 2022.)
(Also see "Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost" - Scrip, 10 Nov, 2022.)
(Also see "Show Me CIIE: Can Foreign Pharma Continue Growth Trajectory In Closing China?" - Scrip, 10 Nov, 2022.)